Diosmectite (DIOSMECTAL) in preventive anti-diarrheic therapy in patients subjected to pelvic radiation
- PMID: 16501441
Diosmectite (DIOSMECTAL) in preventive anti-diarrheic therapy in patients subjected to pelvic radiation
Abstract
Background: The radiation therapy of abdominal-pelvic tumors, determining diarrhea and cramps, could reduce the compliance of the patient and compromise his quality of life. This study attempts to assess the effects of adjuvant therapy with diosmectite (Diosmectal) on the above mentioned side effects from radiotherapy.
Methods: From August 1998 to September 1999, 40 patients (mean age 68) at the Oncological Radiotherapy Division of the Azienda Policlinico of Modena took part in the study: 21 forming the group of patients treated with diosmectite and 19 forming the control group. The radiotherapy was administered with total doses varying from 45 to 70 Gy in both groups with daily doses of 1.8-2 Gy. From the beginning of the therapy the patients in the group treated with Diosmectal, received 6 g daily doses of the drug split into two administrations. The diarrhea was assessed by referring to the Lent Soma score.
Results: In the group of patients not in therapy, an incidence of diarrhea was observed in 77% of subjects while in the group in therapy the incidence of diarrhea dropped to 25% of the cases (p<0.005), with an increase in the latency of the appearance of any diarrhoeic symptoms.
Conclusions: Our data suggests that the administration of diosmectite in a prophylactic manner is capable of reducing the incidence of gastroenteric symptomatology (diarrhea and cramps).
Similar articles
-
[Therapy trends in the prevention of radiation-induced diarrhea after pelvic and abdominal irradiation. Results of a tricenter study].Strahlenther Onkol. 1995 Jan;171(1):49-53. Strahlenther Onkol. 1995. PMID: 7839305 Clinical Trial. German.
-
Oral diosmectite reduces stool output and diarrhea duration in children with acute watery diarrhea.Clin Gastroenterol Hepatol. 2009 Apr;7(4):456-62. doi: 10.1016/j.cgh.2008.12.007. Epub 2008 Dec 13. Clin Gastroenterol Hepatol. 2009. PMID: 19268266 Clinical Trial.
-
Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.Headache. 2008 Jun;48(6):900-13. doi: 10.1111/j.1526-4610.2007.00953.x. Epub 2007 Nov 28. Headache. 2008. PMID: 18047501 Clinical Trial.
-
Clinical evaluation of the intraoral fluoride releasing system in radiation-induced xerostomic subjects. Part 2: Phase I study.Oral Oncol. 2006 Oct;42(9):946-53. doi: 10.1016/j.oraloncology.2005.12.029. Epub 2006 Jun 6. Oral Oncol. 2006. Corrected and republished in: Oral Oncol. 2007 Jan;43(1):98-105. doi: 10.1016/j.oraloncology.2005.12.031. PMID: 16757200 Corrected and republished. Clinical Trial.
-
[Intensity modulated radiation therapy for patients with gynecological malignancies after hysterectomy and chemotherapy/radiotherapy].Zhonghua Zhong Liu Za Zhi. 2007 Apr;29(4):305-8. Zhonghua Zhong Liu Za Zhi. 2007. PMID: 17760262 Chinese.
Cited by
-
Chapter 11.6 Clays and Clay Minerals as Drugs.Dev Clay Sci. 2006;1:743-752. doi: 10.1016/S1572-4352(05)01025-1. Epub 2007 Sep 4. Dev Clay Sci. 2006. PMID: 32362802 Free PMC article. Review.